In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality

Ann Intern Med. 2021 Feb;174(2):JC17. doi: 10.7326/ACPJ202102160-017. Epub 2021 Feb 2.

Abstract

Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19-interim WHO Solidarity Trial results. N Engl J Med. 2020. [Epub ahead of print.] 33264556.

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Aged
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antiviral Agents / therapeutic use*
  • COVID-19 / mortality*
  • COVID-19 Drug Treatment
  • Drug Therapy, Combination
  • Female
  • Hospital Mortality*
  • Hospitalization
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Intention to Treat Analysis
  • Interferon beta-1a / therapeutic use
  • Kaplan-Meier Estimate
  • Length of Stay
  • Lopinavir / therapeutic use
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Respiration, Artificial
  • Treatment Failure
  • World Health Organization

Substances

  • Antiviral Agents
  • Lopinavir
  • remdesivir
  • Adenosine Monophosphate
  • Hydroxychloroquine
  • Alanine
  • Interferon beta-1a